Nasdaq · CIK 0001023024
ANIP ANI PHARMACEUTICALS INC
Insider trading from SEC Form 4. Last filing 12 d ago. Close $73.89 on Oct 9, 2026, +5% from the 52-week low and -23% from the high.
Last 90 days
Net insider value
-$906k
more sold than bought
Buys
0
$0 by 0 insiders
Sells
5
$906k by 4 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
ANIPOct 9, 2026 · close 73.89
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at ANI PHARMACEUTICALS INC, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 22Weak | Stephen P. Carey SVP & CFO sell | $208k 2,850 shares | -2% | +3% from low-24% from high | |
| 36Weak | Nikhil Lalwani PRESIDENT & CEO sell | $383k 5,400 shares | -2% | +3% from low-27% from high | |
| 18Weak | Jeanne Thoma director sell | $72k 1,000 shares | -4% | 0% from low-29% from high | |
| 16Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $35k 500 shares | -1% | +0% from low-29% from high | |
| 29Weak | Stephen P. Carey SVP & CFO sell | $207k 2,850 shares | -2% | +4% from low-26% from high | |
| 13Weak | Krista Davis SVP, CHIEF HR OFFICER sell | $98k 1,000 shares | -2% | +81% from low-2% from high | |
| 16Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $39k 400 shares | -1% | +83% from low-1% from high | |
| 56Moderate | Antonio R Pera director sell | $692k 7,292 shares | -24% | +78% from low0% from high | |
| 53Moderate | Matthew J Leonard director sell | $229k 2,528 shares | -27% | +69% from low-1% from high | |
| 41Moderate | Krista Davis SVP, CHIEF HR OFFICER sell | $161k 1,763 shares | -3% | +71% from low-0% from high | |
| 65Notable | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS sell | $9.0M 100,000 shares | -19% | +70% from low0% from high | |
| 53Moderate | Antonio R Pera director sell | $486k 5,421 shares | -15% | +70% from low0% from high | |
| 65Notable | Jeanne Thoma director sell | $1.9M 21,540 shares | -48% | +68% from low-0% from high | |
| 57Moderate | Patrick D Walsh director sell | $801k 9,000 shares | -11% | +64% from low-3% from high | |
| 60Notable | Matthew J Leonard director sell | $612k 6,937 shares | -42% | +68% from low-0% from high | |
| 65Notable | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS sell | $8.8M 100,000 shares | -16% | +69% from low0% from high | |
| 60Notable | Chad Gassert SVP - CORP. DEV. & STRATEGY sell | $1.7M 20,000 shares | -10% | +64% from low-3% from high | |
| 65Notable | Thomas Haughey director sell | $1.7M 19,341 shares | -35% | +66% from low0% from high | |
| 52Moderate | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS sell | $426k 4,975 shares | -11% | +66% from low0% from high | |
| 52Moderate | Stephen P. Carey SVP & CFO sell | $4.3M 50,000 shares | -22% | +66% from low0% from high | |
| 70Notable | Nikhil Lalwani PRESIDENT & CEO sell | $4.9M 56,960 shares | -12% | +66% from low0% from high | |
| 48Moderate | Ori Gutwerg SVP, GENERICS sell | $508k 5,873 shares | -7% | +66% from low0% from high | |
| 16Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $36k 400 shares | -1% | +66% from low0% from high | |
| 0Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $26k 400 shares | -1% | +22% from low-11% from high | |
| 0Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $25k 400 shares | -1% | +17% from low-14% from high | |
| 37Weak | Ori Gutwerg SVP, GENERICS sell | $53k 881 shares | -1% | +12% from low-18% from high | |
| 43Moderate | Christopher Mutz HEAD OF RARE DISEASE sell | $242k 4,000 shares | -4% | +13% from low-17% from high | |
| 22Weak | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS sell | $54k 700 shares | -0% | +24% from low-9% from high | |
| 10Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $25k 400 shares | -0% | +16% from low-15% from high | |
| 0Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $28k 400 shares | -0% | +29% from low-1% from high | |
| 20Weak | Krista Davis SVP, CHIEF HR OFFICER sell | $121k 1,866 shares | -3% | +22% from low0% from high | |
| 15Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $25k 400 shares | -0% | +15% from low-3% from high | |
| 17Weak | Krista Davis SVP, CHIEF HR OFFICER sell | $61k 1,000 shares | -1% | +14% from low-2% from high | |
| 29Weak | Ori Gutwerg SVP, GENERICS sell | $323k 5,384 shares | -5% | +12% from low-4% from high | |
| 17Weak | Krista Davis SVP, CHIEF HR OFFICER sell | $60k 1,000 shares | -1% | +9% from low-6% from high | |
| 3Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $24k 400 shares | -0% | +11% from low-4% from high | |
| 0Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $22k 400 shares | -1% | +1% from low-13% from high | |
| 53Moderate | Stephen P. Carey SVP & CFO sell | $418k 7,500 shares | -5% | - | |
| 10Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $14k 250 shares | -0% | - | |
| 17Weak | Krista Davis SVP, CHIEF HR OFFICER sell | $60k 1,000 shares | -2% | - | |
| 50Moderate | Nikhil Lalwani PRESIDENT & CEO sell | $1.9M 33,481 shares | -8% | - | |
| 46Moderate | Christopher Mutz HEAD OF RARE DISEASE sell | $375k 6,500 shares | -8% | - | |
| 10Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $15k 250 shares | -0% | - | |
| 0Weak | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. sell | $14k 250 shares | -0% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 29, 2026 | Stephen P. Carey SVP & CFO | SOpen-market sale Common Stock10b5-1 | -2,850 | $73.00 | $208k | 168,993 | 12 d ago |
| Sep 15, 2026 | Nikhil Lalwani PRESIDENT & CEO | SOpen-market sale Common Stock10b5-1 | -5,400 | $71.00 | $383k | 339,089 | 26 d ago |
| Sep 11, 2026 | Jeanne Thoma director | SOpen-market sale Common Stock10b5-1 | -1,000 | $71.53 | $72k | 26,762 | 28 d ago |
| Sep 14, 2026 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -500 | $70.79 | $35k | 73,924 | 28 d ago |
| Aug 31, 2026 | Stephen P. Carey SVP & CFO | SOpen-market sale Common Stock10b5-1 | -2,850 | $72.80 | $207k | 171,843 | 41 d ago |
| Sep 19, 2025 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $98.04 | $98k | 60,186 | Sep 22, 2025 |
| Sep 12, 2025 | Krista Davis SVP, CHIEF HR OFFICER | FTax withholding Common Stock | -1,710 | $97.71 | $167k | 61,186 | Sep 15, 2025 |
| Sep 12, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $98.42 | $39k | 76,074 | Sep 15, 2025 |
| Sep 3, 2025 | Antonio R Pera director | SOpen-market sale Common Stock | -7,292 | $94.94 | $692k | 22,660 | Sep 4, 2025 |
| Aug 25, 2025 | Matthew J Leonard director | SOpen-market sale Common Stock | -2,528 | $90.62 | $229k | 6,864 | Aug 26, 2025 |
| Aug 22, 2025 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock | -1,763 | $91.10 | $161k | 62,896 | Aug 25, 2025 |
| Aug 20, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | SOpen-market sale Common Stockindirect: Held by Esjay LLC | -47,012 | $90.27 | $4.2M | 484,908 | Aug 22, 2025 |
| Aug 21, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | SOpen-market sale Common Stockindirect: Held by Esjay LLC | -52,988 | $90.44 | $4.8M | 431,920 | Aug 22, 2025 |
| Aug 18, 2025 | Jeanne Thoma director | SOpen-market sale Common Stock | -6,865 | $89.76 | $616k | 38,080 | Aug 20, 2025 |
| Aug 20, 2025 | Antonio R Pera director | SOpen-market sale Common Stock | -5,421 | $89.73 | $486k | 29,952 | Aug 20, 2025 |
| Aug 18, 2025 | Jeanne Thoma director | SOpen-market sale Common Stock | -14,675 | $88.87 | $1.3M | 23,405 | Aug 20, 2025 |
| Aug 15, 2025 | Patrick D Walsh director | SOpen-market sale Common Stock | -9,000 | $89.05 | $801k | 70,048 | Aug 18, 2025 |
| Aug 18, 2025 | Matthew J Leonard director | SOpen-market sale Common Stock | -6,937 | $88.17 | $612k | 9,392 | Aug 18, 2025 |
| Aug 14, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | SOpen-market sale Common Stockindirect: Held by Esjay LLC | -47,010 | $89.48 | $4.2M | 584,910 | Aug 18, 2025 |
| Aug 15, 2025 | Chad Gassert SVP - CORP. DEV. & STRATEGY | SOpen-market sale Common Stockindirect: Held by Chali Properties LLC | -20,000 | $86.97 | $1.7M | 173,226 | Aug 18, 2025 |
| Aug 15, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | SOpen-market sale Common Stockindirect: Held by Esjay LLC | -52,990 | $87.15 | $4.6M | 531,920 | Aug 18, 2025 |
| Aug 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $88.87 | $36k | 76,474 | Aug 14, 2025 |
| Aug 12, 2025 | Thomas Haughey director | SOpen-market sale Common Stock | -19,341 | $85.93 | $1.7M | 36,521 | Aug 14, 2025 |
| Aug 12, 2025 | Stephen P. Carey SVP & CFO | MOption exercise Common Stock | +50,000 | $46.49 | $2.3M | 230,863 | Aug 14, 2025 |
| Aug 12, 2025 | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | SOpen-market sale Common Stock | -4,975 | $85.71 | $426k | 40,794 | Aug 14, 2025 |
| Aug 12, 2025 | Nikhil Lalwani PRESIDENT & CEO | SOpen-market sale Common Stock | -56,960 | $85.93 | $4.9M | 411,219 | Aug 14, 2025 |
| Aug 12, 2025 | Ori Gutwerg SVP, GENERICS | SOpen-market sale Common Stock | -5,873 | $86.53 | $508k | 84,024 | Aug 14, 2025 |
| Aug 12, 2025 | Stephen P. Carey SVP & CFO | SOpen-market sale Common Stock | -50,000 | $86.07 | $4.3M | 180,863 | Aug 14, 2025 |
| Aug 12, 2025 | Stephen P. Carey SVP & CFO | MOption exercise Stock Option (right to buy)derivative | -50,000 | $46.49 | $2.3M | 0 | Aug 14, 2025 |
| Jul 18, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | FTax withholding Common Stock | -2,071 | $66.30 | $137k | 76,874 | Jul 21, 2025 |
| Jul 14, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $64.88 | $26k | 78,945 | Jul 14, 2025 |
| Jun 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $61.37 | $25k | 79,345 | Jun 16, 2025 |
| May 22, 2025 | Thomas Haughey director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 55,862 | May 27, 2025 |
| May 22, 2025 | Antonio R Pera director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 35,373 | May 27, 2025 |
| May 22, 2025 | Patrick D Walsh director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 79,048 | May 27, 2025 |
| May 22, 2025 | Renee P Tannenbaum director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 26,957 | May 27, 2025 |
| May 22, 2025 | Matthew J Leonard director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 16,329 | May 27, 2025 |
| May 22, 2025 | Jeanne Thoma director | AGrant or award Common Stock | +4,336 | $0.00 | $0 | 44,945 | May 27, 2025 |
| May 15, 2025 | Ori Gutwerg SVP, GENERICS | SOpen-market sale Common Stock | -881 | $60.07 | $53k | 89,897 | May 16, 2025 |
| May 14, 2025 | Christopher Mutz HEAD OF RARE DISEASE | SOpen-market sale Common Stock | -4,000 | $60.45 | $242k | 107,317 | May 15, 2025 |
| May 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $62.20 | $25k | 79,745 | May 13, 2025 |
| May 9, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | SOpen-market sale Common Stockindirect: Held by Esjay LLC10b5-1 | -700 | $76.83 | $54k | 631,920 | May 13, 2025 |
| Apr 14, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $68.96 | $28k | 80,145 | Apr 14, 2025 |
| Mar 23, 2025 | Stephen P. Carey SVP & CFO | FTax withholding Common Stock | -6,210 | $64.26 | $399k | 180,863 | Mar 25, 2025 |
| Mar 23, 2025 | Nikhil Lalwani PRESIDENT & CEO | FTax withholding Common Stock | -17,455 | $64.26 | $1.1M | 468,179 | Mar 25, 2025 |
| Mar 19, 2025 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock10b5-1 | -1,866 | $65.00 | $121k | 64,659 | Mar 20, 2025 |
| Mar 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $63.33 | $25k | 80,545 | Mar 14, 2025 |
| Mar 7, 2025 | Stephen P. Carey SVP & CFO | FTax withholding Common Stock | -5,150 | $60.62 | $312k | 187,073 | Mar 14, 2025 |
| Mar 7, 2025 | Nikhil Lalwani PRESIDENT & CEO | FTax withholding Common Stock | -17,060 | $60.62 | $1.0M | 485,634 | Mar 14, 2025 |
| Mar 7, 2025 | Ori Gutwerg SVP, GENERICS | FTax withholding Common Stock | -3,314 | $60.62 | $201k | 90,778 | Mar 14, 2025 |
| Mar 7, 2025 | Christopher Mutz HEAD OF RARE DISEASE | FTax withholding Common Stock | -2,874 | $60.62 | $174k | 111,317 | Mar 14, 2025 |
| Mar 7, 2025 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $60.86 | $61k | 66,525 | Mar 10, 2025 |
| Mar 5, 2025 | Ori Gutwerg SVP, GENERICS | MOption exercise Common Stock | +300 | $31.49 | $9,447 | 99,476 | Mar 7, 2025 |
| Mar 5, 2025 | Ori Gutwerg SVP, GENERICS | SOpen-market sale Common Stock | -300 | $60.03 | $18k | 99,176 | Mar 7, 2025 |
| Mar 5, 2025 | Ori Gutwerg SVP, GENERICS | SOpen-market sale Common Stock | -5,084 | $60.00 | $305k | 94,092 | Mar 7, 2025 |
| Mar 5, 2025 | Ori Gutwerg SVP, GENERICS | MOption exercise Stock Option (right to buy)derivative | -300 | $31.49 | $9,447 | 13,204 | Mar 7, 2025 |
| Feb 28, 2025 | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | FTax withholding Common Stock | -627 | $61.89 | $39k | 45,465 | Mar 4, 2025 |
| Feb 28, 2025 | Stephen P. Carey SVP & CFO | FTax withholding Common Stock | -1,861 | $61.89 | $115k | 192,223 | Mar 4, 2025 |
| Feb 28, 2025 | Nikhil Lalwani PRESIDENT & CEO | FTax withholding Common Stock | -12,216 | $61.89 | $756k | 502,694 | Mar 4, 2025 |
| Feb 28, 2025 | Ori Gutwerg SVP, GENERICS | FTax withholding Common Stock | -1,570 | $61.89 | $97k | 99,176 | Mar 4, 2025 |
| Feb 28, 2025 | Christopher Mutz HEAD OF RARE DISEASE | FTax withholding Common Stock | -1,275 | $61.89 | $79k | 114,191 | Mar 4, 2025 |
| Feb 28, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | FTax withholding Common Stock | -1,099 | $61.89 | $68k | 80,945 | Mar 4, 2025 |
| Feb 28, 2025 | Krista Davis SVP, CHIEF HR OFFICER | FTax withholding Common Stock | -1,099 | $61.89 | $68k | 67,525 | Mar 4, 2025 |
| Feb 21, 2025 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $60.20 | $60k | 68,624 | Feb 24, 2025 |
| Feb 12, 2025 | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | AGrant or award Common Stock | +7,834 | $0.00 | $0 | 41,452 | Feb 18, 2025 |
| Feb 12, 2025 | Stephen P. Carey SVP & CFO | AGrant or award Common Stock | +24,808 | $0.00 | $0 | 179,276 | Feb 18, 2025 |
| Feb 12, 2025 | Nikhil Lalwani PRESIDENT & CEO | AGrant or award Common Stock | +91,399 | $0.00 | $0 | 461,777 | Feb 18, 2025 |
| Feb 12, 2025 | Ori Gutwerg SVP, GENERICS | AGrant or award Common Stock | +15,668 | $0.00 | $0 | 92,895 | Feb 18, 2025 |
| Feb 12, 2025 | Christopher Mutz HEAD OF RARE DISEASE | AGrant or award Common Stock | +24,808 | $0.00 | $0 | 101,585 | Feb 18, 2025 |
| Feb 12, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | AGrant or award Common Stock | +14,362 | $0.00 | $0 | 83,014 | Feb 18, 2025 |
| Feb 12, 2025 | Chad Gassert SVP - CORP. DEV. & STRATEGY | AGrant or award Common Stock | +14,362 | $0.00 | $0 | 64,041 | Feb 18, 2025 |
| Feb 12, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | AGrant or award Common Stock10b5-1 | +16,974 | $0.00 | $0 | 72,562 | Feb 18, 2025 |
| Feb 12, 2025 | Krista Davis SVP, CHIEF HR OFFICER | AGrant or award Common Stock | +13,057 | $0.00 | $0 | 62,116 | Feb 18, 2025 |
| Feb 12, 2025 | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | AGrant or award Common Stock | +5,222 | $0.00 | $0 | 46,674 | Feb 18, 2025 |
| Feb 12, 2025 | Stephen P. Carey SVP & CFO | AGrant or award Common Stock | +16,538 | $0.00 | $0 | 195,814 | Feb 18, 2025 |
| Feb 12, 2025 | Nikhil Lalwani PRESIDENT & CEO | AGrant or award Common Stock | +60,932 | $0.00 | $0 | 522,709 | Feb 18, 2025 |
| Feb 12, 2025 | Ori Gutwerg SVP, GENERICS | AGrant or award Common Stock | +10,444 | $0.00 | $0 | 103,339 | Feb 18, 2025 |
| Feb 12, 2025 | Christopher Mutz HEAD OF RARE DISEASE | AGrant or award Common Stock | +16,538 | $0.00 | $0 | 118,123 | Feb 18, 2025 |
| Feb 12, 2025 | Muthusamy Shanmugam HEAD OF R&D, COO-NOVITIUM OPS | AGrant or award Common Stock | +9,574 | $0.00 | $0 | 92,588 | Feb 18, 2025 |
| Feb 12, 2025 | Chad Gassert SVP - CORP. DEV. & STRATEGY | AGrant or award Common Stock | +9,574 | $0.00 | $0 | 73,615 | Feb 18, 2025 |
| Feb 12, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | AGrant or award Common Stock10b5-1 | +11,316 | $0.00 | $0 | 83,878 | Feb 18, 2025 |
| Feb 12, 2025 | Krista Davis SVP, CHIEF HR OFFICER | AGrant or award Common Stock | +8,704 | $0.00 | $0 | 70,820 | Feb 18, 2025 |
| Feb 14, 2025 | Thomas Andrew Rowland SVP, HEAD - ESTABLISHED BRANDS | FTax withholding Common Stock | -582 | $58.92 | $34k | 46,092 | Feb 18, 2025 |
| Feb 14, 2025 | Stephen P. Carey SVP & CFO | FTax withholding Common Stock | -1,730 | $58.92 | $102k | 194,084 | Feb 18, 2025 |
| Feb 14, 2025 | Nikhil Lalwani PRESIDENT & CEO | FTax withholding Common Stock | -7,799 | $58.92 | $460k | 514,910 | Feb 18, 2025 |
| Feb 14, 2025 | Ori Gutwerg SVP, GENERICS | FTax withholding Common Stock | -1,426 | $58.92 | $84k | 101,913 | Feb 18, 2025 |
| Feb 14, 2025 | Christopher Mutz HEAD OF RARE DISEASE | FTax withholding Common Stock | -1,473 | $58.92 | $87k | 116,650 | Feb 18, 2025 |
| Feb 14, 2025 | Krista Davis SVP, CHIEF HR OFFICER | FTax withholding Common Stock | -1,196 | $58.92 | $70k | 69,624 | Feb 18, 2025 |
| Feb 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $59.54 | $24k | 83,478 | Feb 18, 2025 |
| Feb 15, 2025 | Ori Gutwerg SVP, GENERICS | FTax withholding Common Stock | -1,167 | $58.92 | $69k | 100,746 | Feb 18, 2025 |
| Feb 15, 2025 | Christopher Mutz HEAD OF RARE DISEASE | FTax withholding Common Stock | -1,184 | $58.92 | $70k | 115,466 | Feb 18, 2025 |
| Feb 14, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | FTax withholding Common Stock10b5-1 | -1,434 | $58.92 | $84k | 82,044 | Feb 18, 2025 |
| Jan 13, 2025 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -400 | $53.92 | $22k | 55,588 | Jan 13, 2025 |
| Dec 17, 2024 | Stephen P. Carey SVP & CFO | SOpen-market sale Common Stock | -7,500 | $55.79 | $418k | 154,468 | Dec 18, 2024 |
| Dec 13, 2024 | Meredith Cook SR. VP, GENERAL COUNSEL & SEC. | SOpen-market sale Common Stock10b5-1 | -250 | $56.24 | $14k | 55,988 | Dec 16, 2024 |
| Dec 11, 2024 | Krista Davis SVP, CHIEF HR OFFICER | SOpen-market sale Common Stock10b5-1 | -1,000 | $60.00 | $60k | 49,059 | Dec 12, 2024 |
| Nov 26, 2024 | Nikhil Lalwani PRESIDENT & CEO | MOption exercise Common Stock | +30,000 | $29.00 | $870k | 403,859 | Nov 27, 2024 |
| Nov 26, 2024 | Nikhil Lalwani PRESIDENT & CEO | SOpen-market sale Common Stock | -30,000 | $57.95 | $1.7M | 373,859 | Nov 27, 2024 |
| Nov 26, 2024 | Nikhil Lalwani PRESIDENT & CEO | SOpen-market sale Common Stock | -3,481 | $58.30 | $203k | 370,378 | Nov 27, 2024 |
| Nov 26, 2024 | Nikhil Lalwani PRESIDENT & CEO | MOption exercise Stock Option (right to buy)derivative | -30,000 | $29.00 | $870k | 138,027 | Nov 27, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Stephen P. CareySVP & CFO
- Meredith CookSR. VP, GENERAL COUNSEL & SEC.
- Krista DavisSVP, CHIEF HR OFFICER
- Chad GassertSVP - CORP. DEV. & STRATEGY
- Ori GutwergSVP, GENERICS
- Thomas Haugheydirector
- Nikhil LalwaniPRESIDENT & CEO
- Matthew J Leonarddirector
- Christopher MutzHEAD OF RARE DISEASE
- Antonio R Peradirector
- Thomas Andrew RowlandSVP, HEAD - ESTABLISHED BRANDS
- Muthusamy ShanmugamHEAD OF R&D, COO-NOVITIUM OPS
- Renee P Tannenbaumdirector
- Jeanne Thomadirector
- Patrick D Walshdirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.